Company intelligence / Profile preview

Ambys Medicines

South San Francisco, California, United Stateslinkedin.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The company had demonstrated the ability to produce high-quality liver cells at scale that function in vivo as normal healthy liver cells. Their lead program was planned to enter clinical trials in 2023, but the company closed operations in February 2023[1].

Therapeutic areas: Gastroenterology
Modalities: Cell therapyAllogeneic cell therapy
Industry: Biotech

Drug pipeline

1 asset

AMI-918

Pre-clinical

Indications: Acute liver disease

Beyond the preview

Go deeper on Ambys Medicines.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ambys Medicines.

Explore the full profile